Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Anavex Life Sciences nabs patent win for Alzheimer's candidate

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 113
Posts 16,520
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/24/2021 5:05:26 PM
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
georgejjl   Tuesday, 08/31/21 10:41:36 AM
Re: None
Post # of 338536 
Anavex Life Sciences nabs patent win for Alzheimer's candidate
Aug. 31, 2021 10:22 AM ETAnavex Life Sciences Corp. (AVXL)By: Dulan Lokuwithana

Anavex Life Sciences (AVXL +5.2%) is trading higher on below-average volume after the website for the United States Patent and Trademark Office (USPTO) indicated a patent granted for the company covering its lead candidate ANAVEX2-73 for Alzheimer’s disease.

ANAVEX2-73 is an oral small molecule, undergoing studies for multiple indications, including Alzheimer’s disease and Parkinson’s disease.

In July, Anavex (NASDAQ:AVXL) reported promising pre-clinical data for ANAVEX 2-73 to indicate a dose-dependent effect in preventing cognitive impairments in mice.

By H2 2022, the company intends to provide top-line data from a Phase 2b/3 clinical trial for ANAVEX 2-73 in patients with Alzheimer’s disease.

In mid-August, Anavex (AVXL) had enrolled 509 patients in the randomized, double-blind, placebo-controlled study.

Read Next: Anavex Life reports preclinical data for ANAVEX2-73 in Fragile X Syndrome

https://seekingalpha.com/news/3735688-anavex-life-sciences-nabs-patent-win-for-alzheimers-candidate

Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences